Skip to main content

Table 2 All adverse events observed throughout the study period with gradings based on common terminology criteria for adverse events version 4

From: Neurological, functional, and quality of life outcomes following combined mesenchymal stem cell and Schwann cell therapy in spinal cord injury: a 9-year experience

Adverse event

Overall– no. (%)

Causal link with study intervention

Grade I

Grade II

Grade III

Not related

Unlikely

Probable

Headache

34 (70.8%)

34 (70.8%)

-

-

28 (58.3%)

6 (12.5%)

-

Nausea

27 (56.3%)

27 (56.3%)

-

-

27 (56.3%)

-

-

Fever

19 (39.6%)

16 (33.3%)

3 (6.3%)

-

12 (25.0%)

7 (14.6%)

-

Fatigue

8 (16.7%)

8 (16.7%)

-

-

7 (14.6%)

1 (2.1%)

-

Spasticity

5 (10.4%)

5 (10.4%)

-

-

5 (10.4%)

-

-